TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.39
+5.55%Sep 2, 2026, 11:25 UTC
TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis, effective September 2, 2026, and CEO Gavin MacBeath assumed the additional role of Chief Financial Officer.
Sep 2, 2026, 11:00 UTC
TScan Therapeutics announced a strategic reorganization to focus on in vivo cell therapy for solid tumors, including a workforce reduction of approximately 75%, and paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, extending its runway into Q4 2027.
Aug 12, 2026, 11:00 UTC
TScan Therapeutics shared positive initial data from Cohort C of its Phase 1 ALLOHA study, validating its internal commercial-ready manufacturing process.
Source:Aug 12, 2026, 11:00 UTC
TScan Therapeutics dosed the first patient in its Phase 3 ALLOHA-2 study, with topline readout expected mid-2028.
Source:Aug 12, 2026, 11:00 UTC
TScan Therapeutics reported financial results for the second quarter of 2026, with cash and cash equivalents funding operations into the second quarter of 2027.
Source:Jun 3, 2026, 13:19 UTC
Cellares and TScan Therapeutics announced an agreement to evaluate automated manufacturing of TSC-101 for patients with hematologic malignancies.
Source: